Travis Whitfull
Director/Board Member at SIRPant Immunotherapeutics, Inc.
Profile
Travis Whitfull currently works as a Director at SIRPant Immunotherapeutics, Inc.
Travis Whitfull active positions
| Companies | Position | Start |
|---|---|---|
SIRPant Immunotherapeutics, Inc.
 SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
SIRPant Immunotherapeutics, Inc.
SIRPant Immunotherapeutics, Inc. BiotechnologyHealth Technology SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki. | Health Technology |
- Stock Market
- Insiders
- Travis Whitfull
